Definium Therapeutics (NASDAQ:DFTX) Given New $75.00 Price Target at Robert W. Baird

Definium Therapeutics (NASDAQ:DFTX) had its target price boosted by equities research analysts at Robert W. Baird from $57.00 to $75.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Robert W. Baird’s target price suggests a potential upside of 75.27% from the stock’s current price.

Several other brokerages have also weighed in on DFTX. Needham & Company LLC upped their target price on shares of Definium Therapeutics from $50.00 to $66.00 and gave the stock a “buy” rating in a research report on Wednesday. Stifel Nicolaus boosted their price target on Definium Therapeutics from $30.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Canaccord Genuity Group set a $58.00 price target on Definium Therapeutics and gave the stock a “buy” rating in a report on Tuesday, June 30th. Wells Fargo & Company started coverage on Definium Therapeutics in a report on Monday, July 27th. They set an “overweight” rating and a $68.00 price objective for the company. Finally, Leerink Partners set a $52.00 target price on Definium Therapeutics and gave the company an “outperform” rating in a report on Monday, June 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $58.38.

Definium Therapeutics Stock Performance

Shares of DFTX stock opened at $42.79 on Thursday. The stock’s 50-day moving average price is $39.06 and its 200 day moving average price is $26.52. The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $4.27 billion, a PE ratio of -12.48 and a beta of 2.23. Definium Therapeutics has a 52-week low of $8.70 and a 52-week high of $49.70.

Definium Therapeutics (NASDAQ:DFTX) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). As a group, equities research analysts forecast that Definium Therapeutics will post -2.81 EPS for the current year.

Insider Activity at Definium Therapeutics

In other Definium Therapeutics news, insider Mark Sullivan sold 13,008 shares of Definium Therapeutics stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $585,750.24. Following the transaction, the insider owned 320,571 shares in the company, valued at $14,435,312.13. This trade represents a 3.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Brandi Roberts sold 3,013 shares of Definium Therapeutics stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $135,675.39. Following the completion of the transaction, the chief financial officer owned 209,487 shares in the company, valued at $9,433,199.61. The trade was a 1.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 48,096 shares of company stock valued at $2,165,763 over the last three months. Insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Bank of New York Mellon Corp raised its holdings in Definium Therapeutics by 3.2% in the second quarter. Bank of New York Mellon Corp now owns 777,271 shares of the company’s stock valued at $36,563,000 after acquiring an additional 24,349 shares in the last quarter. Caxton Associates LLP bought a new stake in shares of Definium Therapeutics in the 3rd quarter worth about $126,000. Sender Co & Partners Inc. acquired a new stake in shares of Definium Therapeutics in the 3rd quarter valued at about $305,000. Scientech Research LLC bought a new position in shares of Definium Therapeutics during the third quarter worth about $286,000. Finally, Mercer Global Advisors Inc. ADV grew its stake in Definium Therapeutics by 10.5% in the third quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock worth $259,000 after purchasing an additional 2,079 shares in the last quarter. 27.91% of the stock is owned by institutional investors and hedge funds.

Definium Therapeutics News Roundup

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: The Phase 3 Voyage study reportedly showed that DT120 reduced anxiety symptoms by 5.4 points more than placebo on the HAM-A scale, marking the second positive late-stage study highlighted by the company. Definium Says DT120 Phase 3 GAD Study Shows 5.4-Point HAM-A Benefit vs Placebo
• Positive Sentiment: Coverage characterized the results as a major success for Definium’s LSD-based psychiatric drug, driving a sharp advance in the stock and improving confidence in DT120’s prospects in GAD and another potential indication. Definium says LSD-based pill reduces anxiety in late-stage study
• Positive Sentiment: Needham raised its DFTX price target to $66 from $50 and maintained a Buy rating, implying substantial potential upside from the referenced $42.79 price. Investors may also be looking toward an additional September 2026 catalyst. Needham raises Definium Therapeutics price target
• Neutral Sentiment: Trading in DFTX was temporarily halted for pending news before the clinical announcement, reflecting the significance of the expected trial update rather than a change in the company’s fundamentals.
• Negative Sentiment: HC Wainwright reduced multiple EPS forecasts, including its FY2026 estimate to a $3.05 loss per share from $2.10 and its FY2027 estimate to a $1.71 loss from $1.22. The revisions highlight continued operating losses and execution risk despite the encouraging clinical data.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.